New Delhi: The Drugs Controller General of India (DCGI) has approved the completion of clinical trials of the covid-19 vaccine for children aged 5 to 18 years. According to the DGCI report, Phase 2 and 3 clinical trials of the Made in India vaccine will be conducted following the protocol approved by the Hyderabad – based Biological e Ltd.
The trial will be held at 10 locations across the country. The approval was given by the DCGI based on the recommendations of the Covid -19 Expert Committee (SEC).
Earlier, ZyCoV – D, a needle-free Covid -19 vaccine from the indigenously developed Zydus Cadillac, was approved for immediate use. This is the first vaccine in the country for 12–18-year-olds. Meanwhile, 2/3 of Bharat Biotech’s Covaxin for 2 to 18-year-olds is undergoing clinical trials.
There have been reports that the covid immunization vaccine Corbevax of Biological E currently completes 2/3 of clinical trials in adults. It has been announced that by December, Biological E will provide 30 million doses of Corbevax to the Central Government. The ministry had finalized arrangements with the Hyderabad-based Corbevax manufacturers to reserve 30 crore vaccine doses.
